Skip to main content

Table 1 Main characteristics of all studies included in the meta-analysis

From: Prognostic significance of galectin-1 expression in patients with cancer: a meta-analysis

Study Country Cancer Case number Median age (year, range) M/F Stage Gal-1 (±) NO. Cut-off Multivariate analysis HR and 95% CI
Wu [5] Japan CCA 78 NA 50/28 TNM I–IV (45/33) IRS ≥ 3 No SC
Chen [6] China gastric 214 Mean 64.5 129/85 TNM I–IV (138/76) IRS ≥ 2 No SC
Noda [9] Japan GSCC 80 Mean 63.8 39/41 TNM I–IV (22/58) IHC > 50% No SC
Chong [8] China Gastric 111 NA NA TNM I–IV (61/50) IHC > 20% No SC
Zhang [10] China HCC 209 NA 179/30 TNM I–IV (128/81) IHC > 20% No SC
Huang [13] Tainan RCC 45 NA 31/14 TNM I–IV (25/20) H-score > median No SC
Le [14] USA HNSCC 101 Median 58 84/17 TNM I–IV (56/44) IRS ≥ 3 No SC
Schulz [15] Germany Ovarian 150 Median 62 (31–88) 0/150 FIGO I–IV (102/48) IRS > 1 No SC
Chen [7] China Gastric 108 NA 61/47 TNM I–IV (68/40) IRS ≥ 2 Yes Report
You [11] China HCC 162 NA 127/35 TNM I–IV (105/57) IRS ≥ 2 Yes Report
Wu [12] China HCC 386 NA 341/45 TNM I–IV (189/197) NA Yes Report
Kamper [19] Denmark cHL 143 35 78/80 Ann Arbor I–IV (35/108) NA No Report
Ye [20] China LSCC 187 Mean 52.4 179/8 TNM I–IV (102/85) NA No SC
Szoke [17] Hungary NSCLC 94 Mean 58.8 84/10 TNM I–III (40/54) NA No SC
Carlini [18] Argentina NSCLC 103 Median 64 (45–85) 69/34 TNM I–III (53/47) IRS > 1 No SC
Van Woensel [21] Belgium GBM 349 NA NA NA (174/175) Median gene expression No Report
Chou [22] China GBM 45 NA 27/18 NA (34/11) IHC > 35% No Report
Chen [16] China EOC 109 NA 0/109 FIGO (91/18) IRS ≥ 3 Yes Report
  1. CCA cholangiocarcinoma, GSCC gingival squamous cell carcinoma, HCC hepatocellular carcinoma, RCC renal cell carcinoma, HNSCC head and neck squamous cell carcinomas, cHL classic Hodgkin lymphoma, LSCC laryngeal squamous cell carcinomas, NSCLC non-small cell lung cancer, GBM glioblastoma multiforme, EOC epithelial ovarian cancer, NA not available, SC survival curve, IRS immunoreactivity score, IHC immunohistochemistry